MOTS-c Dosage: What the Research Reports

What is MOTS-c, and why is its dosing uncertain?

MOTS-c is a short peptide encoded inside mitochondrial DNA that Lee et al. (2015) showed activates AMPK and improves metabolic measures in mice, but because no human dosing trial has been completed, no established human dose exists.

MOTS-c stands for a 16 amino acid peptide read from the mitochondrial 12S rRNA region. Lee et al. (2015, Cell Metabolism) reported that it works through AMPK, a cellular energy sensor, and that treated mice showed better insulin sensitivity and resistance to diet-induced obesity. Those findings describe an effect in animals, not a demonstrated outcome or a treatment in people. The uncertainty in dosing follows directly from that: the quantitative dose data come from rodents, and rodent doses are set by body weight and route in ways that do not carry over to human use.

What dose of MOTS-c did the research actually use?

The most-cited data come from Lee et al. (2015), where mice received MOTS-c by intraperitoneal injection, meaning injection into the abdominal cavity, dosed per kilogram of body weight rather than as a fixed milligram amount for people.

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

Read the table as research context, not as a plan. A body-weight dose in a 25 gram mouse is not a milligram number a person can copy, and the route used in the study is a laboratory route, not a consumer one. The figures exist to describe the experiment, and they only describe animals.

Can mouse mg per kg doses be converted to a human dose?

Not reliably: animal-to-human scaling is a rough estimation tool for designing early trials, not a personal dose, and it has never been validated for MOTS-c because no human trial has been completed.

Researchers sometimes estimate a human-equivalent starting dose from animal data using body surface area scaling. That method is built to help design a first human study, and it produces a planning estimate, not a proven dose. For MOTS-c there is no completed human trial to confirm any converted number, so treating a scaled figure as a dose would be guessing. This is the core reason the site does not publish a MOTS-c dose: the honest answer is that the human number is not known.

Is there any human data on MOTS-c dosing?

No completed human dosing trial for MOTS-c has been published, so human dose, frequency, half-life, and safety thresholds are all unestablished, and the evidence rests on animal work such as Lee et al. (2015).

It helps to compare this with peptides that do have a human dosing base. GLP-1 class peptides went through large human dose-finding trials, for example Wilding et al. (2021, New England Journal of Medicine) for semaglutide and Jastreboff et al. (2022, New England Journal of Medicine) for tirzepatide. Those trials tested defined doses in thousands of people and reported outcomes. MOTS-c has nothing of that kind. That gap is not a detail; it is the difference between a compound with a human dosing record and one without. MOTS-c is offered as a research material, and there is no approved human therapeutic use.

How does mg to unit math work for a reconstituted peptide? (reference only)

This is arithmetic, not a dose recommendation: once a lyophilized peptide is reconstituted, concentration equals milligrams of peptide divided by milliliters of liquid, and insulin-syringe "units" are simply a volume marking, where 100 units equals 1 mL on a standard U-100 syringe.

Because 100 units equals 1 mL, one unit equals 0.01 mL. So if you know the concentration, you can convert a milligram amount into a volume and into units. The formula is: units equals (target mg divided by concentration in mg per mL) divided by 0.01. The table below shows how that math behaves at a few example concentrations.

Reference arithmetic only. These rows show how concentration math works. They are not a dose, not a recommendation, and not injection instructions. The "1 mg" and "0.5 mg" columns are placeholders chosen to demonstrate the conversion, not target amounts. What a given individual should do, if anything, is a decision for a qualified clinician.

What safety signals appear in MOTS-c research?

Published MOTS-c safety information is limited to animal studies, so human tolerability, side effects, and long-term safety are not established in the literature.

Lee et al. (2015) reported metabolic changes in mice, such as improved insulin sensitivity and reduced diet-induced obesity, but those are efficacy observations in animals, not a human safety profile. Human pharmacokinetics, including half-life and clearance, are not characterized in published human trials. Absence of reported harm in a mouse study is not evidence of human safety, and the correct summary is that the human safety picture is unknown.

Related reading

To go deeper, see the main MOTS-c overview and the companion page on MOTS-c side effects. For background on how peptides work as a class, read what are peptides. For the contrast used above between a compound with a human dosing record and one without, see GLP-1 receptor agonists explained.